Evotec (NASDAQ:EVO) Sees Large Volume Increase – Should You Buy?

Shares of Evotec AG (NASDAQ:EVO) saw an uptick in trading volume on Friday . 427,913 shares were traded during mid-day trading, an increase of 234% from the previous session’s volume of 128,220 shares.The stock last traded at $3.5540 and had previously closed at $3.43.

Analyst Ratings Changes

A number of brokerages have weighed in on EVO. Wall Street Zen raised Evotec from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Berenberg Bank started coverage on Evotec in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evotec in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.00.

Evotec Stock Performance

The firm has a 50 day moving average of $3.37 and a 200-day moving average of $3.54. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC bought a new stake in Evotec in the 2nd quarter valued at $43,000. BNP Paribas Financial Markets raised its holdings in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after acquiring an additional 9,289 shares during the last quarter. Thrivent Financial for Lutherans bought a new stake in shares of Evotec during the third quarter valued at approximately $53,000. Finally, XTX Topco Ltd acquired a new stake in shares of Evotec in the second quarter valued at approximately $66,000. 5.81% of the stock is owned by institutional investors.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.